Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Covid-19: Who, what, when, where and why

If there is one thing we know about the coronavirus, it’s that getting a jump on it helps to limit the number of infections. Clearly the best time to stop this, and all outbreaks, is in its early stages. Both China and the United States have been accused of...
Richard (Rick) Mills | April 13, 2020 |

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...
Streetwise Reports | July 2, 2020 |

Buzz on the Bullboards: New energy, heath, and transport opportunities

Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse. It is where our Bullboards – your Bullboards – are a leading forum to discuss these Canadian-listed small-cap businesses. Stocks on both sides of the border...
Jonathon Brown | October 19, 2023 |

Memphasys, Moderna, Paion - Investments in solutions with potential

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive thi...
Mario Hose | June 2, 2020 |

Buzz on the Bullboards: A diagnosis on the health of the economy

It has been a bit of a stalemate for North American markets this week as indices nudged one way or another. Earnings report have been rolling in, with some major U.S. banks reporting a slowdown in profits, others saw better-than-expected earnings. Traders are tracking an ...
Jonathon Brown | April 20, 2023 |

Triple Threat Canbud Launches New Products Targeting the Hottest Health & Wellness Trends

After its public listing last October, shares in Canbud Distribution Corporation (CSE: CBDX | FSE: CD0) appear poised to move higher as it executes on its three-pronged business model. Canbud is a science and technology company that concentrates its attention on the Hea...
Featured Submission | February 1, 2021 |

As Drone Market Changes, This Small Cap Offers Opportunities

In my first write up about drones, I used the phrase "The Drones are coming." Perhaps now it is more appropriate "The Drones are multiplying like rabbits." The FAA announced that there were more than 122,000 commercial drone pilots in early 2018. Combined with the 87...
Streetwise Reports | November 27, 2019 |

Favourable Ruling for Emerita Resources on the Aznalcollar Zinc-Lead-Silver Project in Spain

Full size / The Aznalcóllar open-pit near Seville in southern Spain ( source ). Good news for Emerita Resources Corp. as the company today announced favourable ruling on the Aznalcóllar Zinc-Lead-Silver Project appeal. This is making headlines in the news at...
Stephan Bogner | October 4, 2019 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...
Streetwise Reports | January 16, 2020 |
1 2 3 4 5 6 7 8 9 10 ...